



ReNewVax Ltd. (“ReNewVax” or “the Company”) is a next generation vaccine company developing therapeutic vaccines targeting some of the world’s most acute bacterial disease challenges.

Exploiting a reverse vaccinology strategy, deploying genomic-led, rational discovery approaches to produce a pipeline of programs that offer protection beyond existing traditional vaccines, ReNewVax is focused on tackling critical pathogens associated with Antimicrobial Resistance (AMR), opening up access and delivering a step-change in global health security.

The company’s lead program RVX-001, is targeted at *Streptococcus pneumoniae* (also known as the pneumococcus). A major cause of global morbidity and mortality from pneumonia, septicaemia and meningitis, *Strep. Pneumoniae* is the third-leading cause of death from bacterial infection globally and the fourth-leading cause of deaths associated with AMR). This is despite the availability of pneumococcal vaccines since 1983, which have generated the largest global market for any vaccine (prepandemic) with consensus annual sales of around \$8.9bn in 2024, projected to grow at a CAGR of 5.6% to ca. \$15bn in 2034.

Existing vaccine technologies work by inducing immunity to a relatively small subset, of the ca. 100 different pneumococcus serotypes. Whilst this approach has led to a reduction in serious pneumococcal disease, the inherent limitations of the technology mean that manufacturing is costly (limiting use largely to high income countries (HICs)), coverage against pneumococcus is limited to around 20% of vaccine serotypes and residual disease burden is significant and growing, with an increasing impact from antimicrobial resistant (AMR) pneumococcal strains. These factors leave important gaps in the market that are fuelling market growth as well as new product development from the dominant players and potential market entrants with an emphasis on improving vaccine coverage or, particularly in the case of middle income countries (MICs), developing generic copies of existing vaccines.

The limitations of existing products have led to the World Health Organisation (WHO) leading calls for a lower cost, universal vaccine to *S. pneumoniae*, that will provide coverage against all strains. RVX-001 is, potentially, the first universal vaccine to protect against this key pathogen.

RVX-001 has been developed with the benefit of £2.1m of grant funding, primarily from the Gates Foundation, Meningitis Now and the UK Medicines Research Council, using a unique approach for selection of protein antigens based on genomic screening of over 25,000 globally sourced clinical isolates to identify proteins that are highly conserved across all pneumococcal serotypes. Preclinical studies have demonstrated protection

against vaccine and non-vaccine strains and the program is ready for progression into IND/CTA-enabling studies. Successful completion of these studies will see RVX-001 entering clinical development in late-2026.

The RVX-001 program will be of interest to a range of partners including market leaders looking to maintain and increase market share, other major vaccine companies looking to extend their portfolios to include this important indication and emerging technology companies looking for key protein targets for novel RNA/DNA approaches.

In addition to RVX-001, ReNewVax is looking to progress further asset opportunities, RVX-002 against *Streptococcus agalactiae* (Group B Strep. or GBS), and RVX-003 against *Streptococcus pyogenes* (Group A Strep. or GAS).

ReNewVax is now raising £15,000,000 in equity capital to enable completion of Phase I clinical studies for RVX-001 (planned in 2026/27) and establish a clear clinical path to approval in the adult vaccination setting, as well as continuing to progress pipeline programs RVX-002 and RVX-003.

Competitor companies developing follow-on conjugate vaccines to pneumococcus have achieved significant valuations on securing early clinical proof of concept, with Affinivax purchased by GSK in 2022 for ca. \$3bn and Vaxcyte having a peak market capitalisation of >\$14bn (Sep. 2024), highlighting the opportunity represented by ReNewVax's novel approach to universal vaccines.